We partner with leading biopharma companies to help them unlock biological insights, tackle therapeutic challenges from new angles and develop novel drugs for a range of complex diseases.
COLLABORATIONS
End-to-end drug discovery offerings
Leverage our drug discovery offerings to enable novel discoveries throughout your drug discovery process.
PARTNERSHIP
Licensing
We are also exploring licensing and commercialisation partnerships for specific assets in our pipeline.
We have consistently delivered results in our collaboration with AstraZeneca, who are progressing four of the most promising targets from five initially selected in Chronic Kidney Disease and Idiopathic Pulmonary Fibrosis into its portfolio. Good progress is also being made toward further target selection in Heart Failure and Systemic Lupus Erythematosus(SLS) use cases following the extension in January 2022 of the collaboration for a further 3 years to include these indications
New strategic collaboration seeks to identify and develop innovative compounds through Hit Identification to the pre-clinical stage.
OUR PARTNERS
Business partners
Academia and non-profit organisations
PARTNERING
We partner with leading pharmaceutical and biotech companies to help them unlock biological insights and tackle complex therapeutic challenges.